Sarda Proteins plans eight-fold jump in authorized capital to ₹100 cr
Nano-cap edible oil company prepares for major equity dilution; board to meet on 4 July 2026 to seek shareholder approval for capital increase.
— 1 earlier story on Sarda Proteins Ltd. →What's new
- Board to meet 4 July to hike authorized capital from ₹13 cr to ₹100 cr
- Also to alter MOA objects clause and seek shareholder ratification via EGM
- Move suggests groundwork for a significant equity issuance after Onix entry
Why this matters
For a company with just ₹84 cr market cap, an eight-fold increase in authorized capital is a massive signal of intent. It implies management is preparing to raise substantial equity, likely through rights or preferential allotment, which would deeply dilute existing shareholders. The absence of specific quantum or mode leaves the timing and structure of any potential capital raise uncertain.
What we're watching
- Shareholder response at the EGM: will retail holders approve the dilution?
- Whether the capital raise is linked to Onix Renewable's expansion plans
- Any detail on mode of issuance: rights, preferential, or QIP
The full read
Sarda Proteins is preparing for something big. Its board will meet on 4 July 2026 to propose an eight-fold increase in authorised equity share capital from ₹13 crore to ₹100 crore. For a nano-cap with a market capitalisation of just ₹84 crore, that magnitude of headroom is a clear signal: management is laying the groundwork for a substantial equity issuance, most likely a rights issue or preferential allotment. The filing also includes amending the objects clause of the MOA and calling an extraordinary general meeting to secure shareholder approval. The timing follows the recent change in control by Onix Renewable, suggesting the capital raise may be tied to their growth plans. But the meeting is just a procedural first step. No amount, mode, or timeline has been disclosed. What is certain: if the full headroom is used, existing shareholders face severe dilution. Without specifics, the per-share impact remains uncertain.
Questions answered
- Why is Sarda raising authorized capital?
- The board proposes an eight-fold increase from ₹13 cr to ₹100 cr to enable a future equity issuance. The filing does not specify the fundraise amount or mode.
- How does this relate to Onix Renewable?
- Onix recently completed an open offer and warrant conversion, gaining control. The capital hike may facilitate Onix's growth plans or debt reduction, but no direct link is confirmed.
- What will happen at the EGM?
- Shareholders will vote on increasing authorized capital, altering the MOA objects clause, and any related resolutions. Approval requires a simple majority.
- Is this a done deal?
- No. The board is only meeting to consider the proposal; it is not a final decision. Shareholder approval is required.
- How dilutive could this be?
- With authorized capital jumping from ₹13 cr to ₹100 cr, the company could issue up to ₹87 cr of new equity. At current market cap of ₹84 cr, that could more than double the share count, severely diluting existing holders.
Sarda Proteins Ltd.
Latest quarter · Mar 2026
Strength & growth
Story so far
All notes on SRDAPRT →- 1 Jul 2026 · 4:29 PM IST Sarda Proteins plans eight-fold jump in authorized capital to ₹100 cr
- 1d ago Sarda Proteins loses MD, three directors after Onix open offer